The aim of this study was to determine the prevalence of extended spectrum beta-lactamases (ESBLs) production in hospital strains of Enterobacteriaceae isolated from various clinical specimens (urine, blood and wound swabs) from hospitalized patients at the Military Medical Academy, Belgrade, Serbia. During six months of study, a total of 1034 isolates of Enterobacteriaceae were tested for antimicrobial susceptibility and screened for ESBL production according to standard methods. The overall prevalence of ESBL production in the hospital isolates of Enterobacteriaceae was 57.4%. Among the isolates, minimum frequency of resistance was found for amikacin (25.2%), and maximum for ampicillin (84.5%). The strain resistant to imipenem could not be isolated. Resistance to the tested antibiotics was higher in ESBL producers than non-producers (P < 0.05). Among Escherichia coli isolates, the prevalence of ESBL production was less than 50% (33.9%). ESBLs were most often produced by isolates of Serratia spp. (85.2%) and Klebsiella spp. (81.8%). Blood specimens were the most common sources of ESBL-producing isolates (84.0%). These findings might help clinicians in deciding the appropriate empirical treatment for intrahospital patients and emphasize the increasing problem of antimicrobial resistance in Serbia.
GRAM-NEGATIVE bacterial infections represent a major therapeutic problem because of their importance and abundance 1 . Beta-lactams include the maximum number of antibiotics, and the most used in the clinical practice 2 . Except majority of mycobacteria and intracellular pathogens, most bacteria are susceptible to beta-lactams 3 , including penicillin, cephalosporin, carbapenem and monobactam. Carbapenems are beta-lactams with a broad spectrum of activity; in clinical practice, the most commonly used are imipenem and meropenem.
Some bacteria synthesize beta-lactamases that inactivate the antibiotic or lead to changes in the structure of the drug. These enzymes lead to the development of resistance to penicillin, cephalosporin and carbapenem 4, 5 . The expansion of these enzymes, as well as the emergence of new enzymes with a broad spectrum of activity have been recently reported 6 . Many Gram-positive and Gram-negative bacteria have the ability to produce beta-lactamases. Some enzymes are mediated by plasmids, while others are mediated by bacterial chromosomes. Most of the plasmid beta-lactamases are secreted constitutively and have the tendency to be transmitted from one bacterial species to another 7 . Antimicrobial resistance caused by widespread and indiscriminate use of antimicrobial agents has important implications on treatment outcomes and healthcare costs 8 . It is believed that 50-67% of all nosocomial infections are caused by pathogens resistant to antimicrobials 9, 10 . Members of the Enterobacteriaceae family usually secrete TEM-1, TEM-2 and SHV-1 beta-lactamases which provide resistance against beta-lactam ring containing antibiotics. These beta-lactamases are commonly found on portable plasmids, but have also been found in the transposons and on bacterial chromosomes. Mutations in these genes may result in the replacement of one or more amino acids in the active part of the enzyme, which leads to an increase in the number of substrates they affect. These mutants are called extended spectrum betalactamases (ESBLs) 11 . These beta-lactamases hydrolyse broad-spectrum cephalosporins, i.e. oxiaminocephalosporins (ceftazidime, cefotaxime, ceftriaxone), monobactams, ureidopenicillins, and some of them hydrolyse cephamycin, while having no effect on the carbapenems 12, 13 . This leads to frequent reports on the emergence of resistance to these antibiotics in other microorganisms, as well as enterobacteria [14] [15] [16] [17] . Very often, isolates that produce these enzymes also show resistance to other groups of antimicorobial agents such as fluoroquinolones, aminoglycosides, tetracycline and co-trimoxazole 18, 19 . Till now about 500 different types of beta-lactamases have been reported from clinical isolates 20, 21 . ESBLs were detected in the eighties of the last century, first in Germany and France, and later throughout the world [22] [23] [24] . They are practically found in all Enterobacteriaceae and in Pseudomonas aeruginosa 25 . Since the genes for ESBLs are located on the plasmids, they can spread amongst the bacteria; even among different species of Gram-negative bacteria 26 . ESBLs may be the cause of therapy failure in hospitals [27] [28] [29] . Their presence in bacterial strains causing hospital outbreaks, especially in intensive care units, oncology departments, burn units and neonatal wards, can have devastating and fatal consequences 30, 31 . The Infectious Diseases Society of America included ESBL-producing strains of Escherichia coli and Klebsiella pneumoniae in a list of six resistant pathogens, causative agents of infectious diseases, for which new therapeutic options are urgently needed 32 . In addition, extensive and expensive infection control measures must be tailored for outbreaks caused by multiresistant Gram-negative pathogens 33 . The frequency of ESBLs shows specific geographic distribution 34 . It is greater in developing countries than in developed countries, because the former have limited access to new antibacterial agents 35 . In fact, it has been noted that the production of ESBLs is somewhat less common in Europe than in Latin America and Asia, but much more frequent than in North America 36 . In Europe, the production of ESBLs is significantly lower in the northern countries compared to those in the south and east (e.g. Serbia) 37 . For detection of ESBLs, as a first step, the sensitivity test with cephopodoxime or cefotaxime and ceftazidime is recommended 38 . The next step is the disc diffusion method using cephalosporin with and without clavulanic acid. Further detection of the enzymes can be continued by molecular methods, which are more sensitive but also more complicated and expensive to perform.
The aim of this study was to determine the prevalence of ESBL production in hospital strains of Enterobacteriaceae isolated from different clinical specimens (urine, blood and wound swabs) from hospitalized patients, with a minimum stay of 4 days, at the Military Medical Academy (MMA) hospital, Belgrade, Serbia. Also, the significance of differences in terms of the frequency of ESBL production among hospital strains of Enterobacteriaceae, as well as between different types of samples was determined. Additionally, the significance of differences in terms of the sensitivity of clinical isolates to other classes of antibiotics was monitored.
Materials and methods

Study settings
This study was conducted in the Medical Microbiology Laboratory of military hospital at MMA, between September 2012 and February 2013.
One thousand thirty-four clinical isolates of Enterobacteriaceae from various clinical specimens were recovered and identified following conventional procedures 39 . These clinical specimens were urine (698 isolates), blood (47 isolates) and wound swabs (289 isolates).
Collection of specimens
Specimens of urine were received into sterile plastic containers and were processed immediately for detection of Enterobacteriaceae.
The specimens of blood were extracted under aseptic conditions and transferred immediately to sterile bottles containing brain heart infusion broth 40 . Specimens from wounds were taken as swabs, placed on transport media and analysed as soon as possible.
Bacterial isolates
All clinical samples were inoculated on blood agar and MacConkey agar. All inoculated plates were incubated aerobically at 37°C for 24 h.
Further identification of the isolates was carried out by a study of their various colonial morphology and biochemical reactions such as coagulase, indole, urease, methyl red, Voges-Proskauer, citrate utilization and sugar fermentation tests as previously described 41 and confirmed by API 20E identification system (bioMerieux, Marcy l'Etoile, France).
Antibiotic susceptibility testing
Susceptibility to beta-lactam and non-beta-lactam antibiotics was performed on Mueller-Hinton agar plates (Oxoid, England) using the Kirby-Bauer disk diffusion method, according to the CLSI guidelines 39 . The antibiotic disks contained ampicillin (10 μg), cefalexin (30 μg), ceftriaxone (30 μg), ceftazidime (30 μg), imipenem (10 μg), gentamicin (10 μg), amikacin (30 μg), ciprofloxacin (5 μg), nitrofurantoin (50 μg) and trimethoprim-sulfamethoxazole (25 μg) (Oxoid, England).
Standardized inoculum (0.5 McFarland standard turbidity) of each isolate was spread on Mueller-Hinton agar plates (150 mm in diameter). Then, 8-9 antibiotic disks were placed on each plate at the recommended distance from each other. All plates were incubated aerobically at 37°C for 24 h before the zone sizes were recorded following CLSI guidelines 39 . Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as comparison standards for antimicrobial susceptibility.
Detection of ESBL isolates
The isolates with diameter zones of 10-18 mm for ceftazidime were further screened for ESBL production. Detection of ESBL isolates was performed using the double-disk synergy test (DDST) and confirmed by double-disk diffusion test (DDDT) 39 . DDST was done using amoxicillin/clavulanic acid as beta-lactamase inhibitor. Disks containing ceftriaxone (30 μg), cefotaxime (30 μg) and ceftazidime (30 μg) were placed on Mueller-Hinton agar, streaked with a 0.5 McFarland bacterial suspension of isolates, 30 mm (centre to centre) from the amoxicillin/clavulanic acid (20 μg/10 μg) disk. The plates were incubated at 37°C for 24 h. Synergy between the disks towards the betalactamase inhibitor was regarded as presumptive ESBL production 42 . DDDT was used to confirm the results of DDST. Four disks containing third generation cephalosporins with and without clavulanic acid were prepared as follows: ceftazidime (30 μg), ceftazidime + clavulanic acid (10 μg), cefotaxime (30 μg) and cefotaxime + clavulanic acid (10 μg). These disks were placed on Mueller-Hinton agar inoculated with standardized inocula of potential ESBLproducing isolates, at the recommended distance from each other 39 . The plates were incubated aerobically at 37°C for 4 h. The positive result (ESBL production) was defined as 5 mm increase in inhibition zone diameter around combination disks with clavulanic acid versus its standard zone when tested alone. E. coli ATCC 25922 was used as the negative control, and Klebsiella pneumoniae ATCC 700603 as the positive control.
Statistical analysis
The results were analysed using chi-square (χ 2 ) test. P-values < 0.05 were considered to be statistically significant. Statistical analysis was done using the software STATISTICA v.10.0 (StatSoft, Inc., USA).
Ethical declaration
This was a laboratory-based study and did not involve any intervention concerning the patients directly.
Results and discussion
The overall prevalence of ESBL production in hospital isolates of Enterobacteriaceae was 57.4% (Table 1) . The strains resistant to carbapenem imipenem were not isolated. Among the other classes of antibiotics (other than betalactams), the minimum frequency of resistance was found in aminoglycoside amikacin (25.2%) and fluoroquinolone ciprofloxacin (41.7%). The highest frequency of resistance was found for ampicillin (84.5%), trimethoprim/ sulphamethoxazole (66.1%) and nitrofurantoin (63.2%) ( Table 1 ). There was a statistically significant difference in the percentage of resistant strains of Enterobacteriaceae to ceftazidime, depending on the clinical specimen (Table 1 and Figure 1) .
The frequency of ESPL production was highest in Serratia spp., Klebsiella spp., Proteus mirabilis and Morganella morgani, and lowest in Escherichia coli (Table 2 and Figure 2) .
In case of different clinical specimens, the highest rate of resistance was recorded in strains isolated from the blood (84.0%) (Figure 1 ). This is in contrast to most studies in which the highest percentage of ESBL producers was recorded in samples of urine [43] [44] [45] [46] . The highest frequency of resistance to gentamicin was found in Providencia spp. and M. morgani, and the lowest in E. coli (Table 3 ). The highest frequency of resistance to amikacin was also found in Providencia spp. and M. morgani, and the lowest in Serratia spp. and E. coli (Table 3) .
The highest frequency of resistance to ciprofloxacin was found in Providencia spp. and M. morgani, and the lowest in Proteus mirabilis and Serratia spp. (Table 4) .
The highest frequency of resistance to trimethoprim/ sulphamethoxazole was found in Serratia spp. and Providencia spp. and the lowest in E. coli ( Table 5 ).
The highest frequency of resistance (100%) to nitrofurantoin was found in Proteus vulgaris, Providencia rettgeri and M. morgani, and the lowest in E. coli (Table 6) .
Penicillins acting on enterobacteria are divided into four groups: aminopenicillins, acilureidopenicillins, carboxypenicillins and amidinopenicillins 3 . The most important aminopenicillins are ampicillin and amoxicillin. Enterobacteriaceae inherently susceptible to these anti- Given such a high prevalence of resistance, these antibiotics should not be considered in the empirical treatment of nosocomial infections in the study clinic, even in infections of the urinary tract. E. coli, Klebsiella spp. and P. mirabilis may be susceptible to the first generation of cephalosporins, while Serratia spp. and Enterobacter spp. are considered to be resistant 3 . Thus, in our hospital isolates of E. coli frequency of resistance to cephalexin was 57.1% (out of 359 tested isolates), in Klebsiella spp. 87.2% of the isolates were resistant (out of 47 tested), in P. mirabilis 76.9% of the isolates were resistant (out of 104 tested), in Serratia spp. the frequency of resistance was 86.7% (out of 30 tested isolates) and in Enterobacter spp., there 91.9% of the isolates were resistant (out of 74 tested).
With regard third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime), enterobacteria without acquired resistance mechanisms were found to be generally sensitive 3 . The most important mechanism of acquired resistance of Enterobacteriaceae to third-generation cephalosporins in hospitals around the world is the production of various ESBLs 47 . The frequency of this resistance mechanism is considered to be higher than those reported due to inconsistencies in reporting and difficulties in proving it. Increased prevalence of ESBL-producing strains of Enterobacteriaceae from all parts of the world has been reported recently 48 . The overall prevalence of ESBL production in this study was 57.4% (Table 1 ). The overall prevalence of ESBLs produced by enterobacteria in European countries ranged from 1% to 5% in the countries of Northern Europe and from 39% to 47% in Eastern Europe and Turkey 49 . However, a recent study in Germany has recorded ESBL production in 83.6% of human isolates, indicating an alarming increase in this problem in the developed countries 50 . The same trend has also been recorded in other countries around the world 34, 51 . The prevalence of ESBL production among clinical isolates of E. coli in this study was 33.9% (out of 401 tested isolates, 136 were ESBL producers). In other European countries, the prevalence of ESBL production in strains of E. coli ranged from 4.0% to 31.9% (refs 45, 52 and 53) .
The prevalence of ESBL production among isolates of Klebsiella spp. was 81.8% (out of 66 tested isolates, 54 were ESBL producers). This result far exceeds the values recorded in neighbouring countries, viz. 18.9% in Croatia 54 and 24.3% in FYR Macedonia 55 . The highest prevalence of ESBL production among strains of Klebsiella pneumoniae has been observed in China (51%), Turkey (48.8%) and Latin America (47.3%) 47 . Results of the present study are consistent with those from the literature highlighting that prevalence of ESBL strains of K. pneumoniae is significantly higher than that of E. coli, in the European countries and USA [55] [56] [57] [58] . The situation is reversed in the countries of Asia, Africa and South America 43, 46, 59, 60 . Isolates from most other enterobacteria were also ESBLs producers, especially strains of Enterobacter spp. 52, 61 , Citrobacter spp. 47 , Serratia spp. 43, 46 and P. mirabilis 45, 47, 62 . In this study, only among the isolates of E. coli was the prevalence of ESBL production less than 50%. ESBLs were most often produced by isolates of Serratia spp. (85.2%) and Klebsiella spp. (81.8%) ( Table 2 ). The isolates of P. vulgaris showed resistance in 100% of the cases, but this result must be taken conditionally due to the small number of isolates. This is consistent with the results from other Eastern European countries [63] [64] [65] , and in contrast with those from Asian countries 59, 66 . The best sensitivity to aminoglycosides was shown by E. coli and Serratia spp.; 40.4% of the isolates of E. coli and 57.1% of the isolates of Serratia spp. were resistant to gentamicin, while 10.9% of the isolates of Serratia spp. and 12.0% of E. coli strains were resistant to amikacin (Table 3 ). This is in line with data from the literature, which show that amikacin is still effective in many strains resistant to gentamicin 3 . The frequency of resistance to gentamicin was highest among isolates of Providencia spp. (83.3-89.6%) and M. morgani (71.4%). In case of amikacin, the percentage of resistant isolates was 44.7-54.0 in Providencia spp. and 60 in M. morgani. High prevalence of resistance to amikacin was observed in P. mirabilis (39.8%), while the strains of Klebsiella spp. and Serratia spp. were relatively well-sensitive to this drug, in spite of the high prevalence of ESBL production ( Table 2) . Despite the application of amikacin for many years in the study hospital, the overall sensitivity of enterobacteria to this antibiotic has been preserved (25.2% of resistant isolates). A good sensitivity of enterobacteria to amikacin is also recorded in other regions of the world 46, 51, 67 . The susceptibility to ciprofloxacin was shown by the isolates of P. mirabilis (12.1% of resistant isolates) and Serratia spp. (24.6% of resistant isolates; Table 4 Table 5 ).
The isolates of Proteus spp., Providencia spp. and M. morgani showed nearly 100% resistance to nitrofurantoin, which is in accordance with their innate resistance 3 . Significant sensitivity to nitrofurantoin was found only in E. coli (37.2% of resistant isolates) and Citrobacter spp. (60.4% of resistant isolates) ( Table 6 ). Taking into account the inherent sensitivity, applying this antibiotic only to isolates of E. coli and Citrobacter spp. from the urine seems valid, because the clinical response of susceptible strains (90% of clinical isolates) can only be expected in those cases 3 . Other enterobacteria almost always have been found to be resistant. Considering that the response to this drug is less satisfactory and requires long-term therapy, it remains an alternative antibiotic more than the drug of first choice 68 . The results of the present study show that the antibiotic of choice in the treatment of serious infections caused by Enterobacteriaceae is imipenem. This has been confirmed by many other studies as well 45, 69, 70 . Statistical comparison of frequency of resistance to antibiotics other than beta-lactams between hospital isolates that produced ESBLs and non-producing strains was performed in this study. There was a statistically significant higher prevalence of resistance (P < 0.05) to gentamicin, amikacin, ciprofloxacin, nitrofurantoin and trimethoprim/sulphamethoxazole in all tested isolates of Enterobacteriaceae that produced ESBLs in comparison to non-producers.
Conclusion
ESBLs were found in all species of Enterobacteriaceae isolated from various clinical specimens from intrahospital patients (urine, blood and wound swabs).
ESBLs were significantly more in Klebsiella spp. and Serratia spp. (81.8% and 85.2% respectively), and rarely occurred in isolates of E. coli (33.9%).
The tested isolates that produced ESBLs were significantly more resistant to other classes of antibiotics (other than beta-lactams). This does not include enterobacteria which are inherently resistant to certain classes of antibiotics.
Following imipenem, the clinical isolates of Enterobacteriaceae showed highest sensitivity, i.e. lowest frequency of the resistance to aminoglycoside amikacin, where the overall prevalence of 25.2% of resistant isolates was observed.
The results of this study showed that the prevalence of ESBL-producing Enterobacteriaceae isolates from intrahospital patients was very high and was among the highest in Europe. This emphasizes the need for urgent interventions in terms of introducing a stringent control of antibiotic usage, strict application of hygienic measures and increasing awareness among health professionals and the general public.
